American Chemical Society
jm1c01599_si_004.pdb (290.3 kB)

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Download (290.3 kB)
posted on 2021-10-26, 19:41 authored by Thomas J. Tucker, Mark W. Embrey, Candice Alleyne, Rupesh P. Amin, Alan Bass, Bhavana Bhatt, Elisabetta Bianchi, Danila Branca, Tjerk Bueters, Nicole Buist, Sookhee N. Ha, Mike Hafey, Huaibing He, John Higgins, Douglas G. Johns, Angela D. Kerekes, Kenneth A. Koeplinger, Jeffrey T. Kuethe, Nianyu Li, BethAnn Murphy, Peter Orth, Scott Salowe, Aurash Shahripour, Rodger Tracy, Weixun Wang, Chengwei Wu, Yusheng Xiong, Hratch J. Zokian, Harold B. Wood, Abbas Walji
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. Starting from second-generation lead structures such as 2, we were able to refine these structures to obtain extremely potent bi- and tricyclic PCSK9 inhibitor peptides. Optimized molecules such as 44 demonstrated sufficient oral bioavailability to maintain therapeutic levels in rats and cynomolgus monkeys after dosing with an enabled formulation. We demonstrated target engagement and LDL lowering in cynomolgus monkeys essentially identical to those observed with the clinically approved, parenterally dosed antibodies. These molecules represent the first report of highly potent and orally bioavailable macrocyclic peptide PCSK9 inhibitors with overall profiles favorable for potential development as once-daily oral lipid-lowering agents. In this manuscript, we detail the design criteria and multiparameter optimization of this novel series of PCSK9 inhibitors.